3 AI Healthcare Stocks Helping Investors Find The Next Breakthrough In Cancer Care
Energy driven inflation remains in focus, and central banks are still cautious, which keeps pressure on healthcare budgets and pushes providers to do more with less. That is where transformative AI healthcare stocks come in. These companies aim to cut waste, sharpen diagnoses, and support leaner staffing. This article highlights three stocks from the Transformative AI Healthcare screener that illustrate how this theme may be relevant for a diversified portfolio.
The three stocks covered below are only a starting sample. The full screen surfaced three more AI healthcare companies with equally compelling narratives that are not covered in this article. To identify and analyze the ideas that best fit your portfolio, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener.
Telescope Innovations (CNSX:TELI)
Telescope Innovations is a Vancouver based chemical technology company that builds hardware, software and lab tools that help pharmaceutical and chemical customers analyze reactions in real time, while also selling intellectual property and research services. The business currently reports about CA$7.3 million in revenue from chemicals related activity, giving a sense of its early commercial scale. With a market cap of roughly CA$33.5 million, Telescope Innovations sits firmly in microcap territory, which can mean higher risk but also more sensitivity to new contracts and partnerships.
Investors looking at Telescope Innovations are really looking at whether its automation and AI ready lab platforms can gain wider adoption across big pharma and specialty chemicals. Recent contracts to deploy Self Driving Lab systems with global pharmaceutical groups and partnerships with Pfizer, Standard Lithium and AGI Group show that large industry players are at least testing its technology at meaningful sites. At the same time, the company is still loss making with a Return on Equity that is deeply negative and it relies on external borrowing with less than a year of cash runway, alongside recent shareholder dilution. That mix of high commercial interest and clear financial strain is exactly what makes Telescope worth a closer look for investors who can tolerate sharp swings in sentiment.
Interest in Telescope Innovations seems to be accelerating, yet the balance sheet tells a tougher story. Before sentiment changes again, review the Telescope Innovations Telescope Innovations financial health report
Build your own AI healthcare shortlist
Telescope Innovations and the two other AI healthcare stocks in this article all surfaced from a single Simply Wall St screen, but the real edge comes from creating filters that match your own style. Use our flexible Screener to combine metrics like valuation, growth potential, balance sheet strength and risks, or lean on the foundations of our curated Investing Ideas.
Profound Medical (TSX:PRN)
Profound Medical is a Mississauga based medical device company that develops AI powered, MRI guided systems for incision free ablation of diseased tissue, led by its TULSA PRO prostate therapy platform and Sonalleve system for conditions such as uterine fibroids and painful bone metastases. The company generates about $19 million in Medical Technology revenue from markets including Canada, the US and Germany, and currently has a market cap of roughly CA$356 million, placing it in the smaller end of the listed medtech peer group.
Profound Medical sits at the crossroads of AI, imaging and minimally invasive cancer care, which is why the CAPTAIN trial data released in July 2026 drew attention. Early readouts suggest the TULSA Procedure may preserve sexual function and continence better than robotic surgery, while management still guides to about $25 million in revenue for 2026. That trajectory comes with clear trade offs. The company is loss making with a P/S multiple well above sector averages, relies entirely on external funding for its liabilities and has recently diluted shareholders, while executive pay runs higher than many peers. For investors who can handle those risks, the combination of rapid forecast growth, an improving loss profile and emerging partnerships in prostate cancer workflows makes Profound Medical a noteworthy name in the space.
Profound Medical’s AI driven ablation story is gaining attention, yet the real tension lies in how its growth outlook compares with today’s price and funding risks. Get the full picture in the 1 key reward and 1 important warning sign
Perimeter Medical Imaging AI (TSXV:PINK)
Perimeter Medical Imaging AI focuses on imaging tools that help surgeons see cancer margins more clearly in the operating room. It earns about $2.1 million in revenue from Medical Imaging Systems, primarily through its Perimeter S Series OCT platform, Claire OCT with ImgAssist AI, and related consumables for hospitals and cancer surgery centers. The company has a market cap of roughly CA$52.2 million, which keeps it firmly in small cap territory.
Perimeter Medical Imaging AI sits at the sharp end of AI supported breast cancer surgery, where even small gains in margin assessment can mean fewer repeat operations for patients. Forecast revenue growth of around 48% a year is set against minimal current revenue, ongoing losses and a history of shareholder dilution. This positions the company as a high risk, early stage story. The stock trades below one internal cash flow estimate, it has recently attracted external coverage with a Buy rating and price target, and June’s INOVAIT and Mitacs funding to improve the Claire OCT AI architecture suggests fresh technical momentum that many investors are not yet watching closely.
Perimeter Medical Imaging AI sits at the crossroads of AI, breast cancer surgery and fresh grant funding, yet many investors still treat it as a niche microcap. See how the analysis report for Perimeter Medical Imaging AI reframes the risk and identifies where the real inflection point might be hiding.
Seeking Fresh Alternatives Beyond AI?
New ideas move fast and so do prices. Spot stocks building quiet momentum before headlines catch up and valuations start flying. These lists stay under the radar for now, act now.
- Track steady compounding potential with resilient companies by running through the 8 resilient stocks with low risk scores while it still feels like a quiet corner of the market.
- Explore structural demand for secure infrastructure by scanning the 36 power grid technology and infrastructure stocks and review electricity and grid modernisation stories.
- Find cash generative AI prospects by filtering the 70 profitable AI stocks that aren't just burning cash and identify businesses where revenue and margins matter as much as the story.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com